Relmada Therapeutics, Inc. RLMD Unrealized Gain (Loss) on Investments
Unrealized Gain (Loss) on Investments at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:UnrealizedGainLossOnInvestments.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s unrealized gain (loss) on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s unrealized gain (loss) on investments?
- Relmada Therapeutics, Inc. (RLMD) reported unrealized gain (loss) on investments of -$540.1K in Q1 2026.
- How has Relmada Therapeutics, Inc.'s unrealized gain (loss) on investments changed year-over-year?
- Relmada Therapeutics, Inc.'s unrealized gain (loss) on investments decreased by 446.8% year-over-year, from $155.73K to -$540.1K.
- What is the long-term trend for Relmada Therapeutics, Inc.'s unrealized gain (loss) on investments?
- Over 3 years (2021 to 2025), Relmada Therapeutics, Inc.'s unrealized gain (loss) on investments has grown at a -13.3% compound annual growth rate (CAGR), from -$611.38K to $398.25K.
- What does unrealized gain (loss) on investments mean?
- Represents the change in fair value of investment securities held by the company that have not yet been sold. This metric reflects market-driven fluctuations in the value of the company's portfolio, providing insight into the volatility of non-operating assets.